Skip to content

Henry Schein HSIC Pre-tax stock-based compensation cost

Pre-tax stock-based compensation cost at other companies

Medline, Inc.
 logo
Medline, Inc. MDLN
Solventum logo
SolventumSOLV
West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
Medtronic logo
MedtronicMDT

Other financials

Income statement

See full
Revenue$3.4B+6.3%
Gross profit$1.1B+7.0%
Operating income$182.0M+4.0%
Net income$107.0M-2.7%
EPS (diluted)$0.92+4.5%

Balance sheet

See full
Cash & equivalents$138.0M+8.7%
Total debt$3.7B+17.2%
Total equity$3.3B-1.3%
Total assets$11.3B+7.9%

Cash flow

See full
Operating cash flow-$97.0M-362%
CapEx$25.0M-19.4%
Free cash flow-$122.0M-2,133%

Valuation

See full
Market cap$9.1B-0.6%
Enterprise value$12.69B+4.2%
P/E23.1×+0.5×
P/S0.7×0.0×

Profitability

See full
Gross margin31.2%-0.4pp
Operating margin4.9%-0.2pp
Net margin3%-0.3pp
FCF margin3.3%-1.0pp

Returns & leverage

See full
Return on equity12%+0.2pp
Debt / equity1.1×+0.2×
Current ratio1.4×0.0×

Where this comes from

Reported directly by Henry Schein in its filing.

Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.

The official record: Henry Schein’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Henry Schein's pre-tax stock-based compensation cost.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Henry Schein's pre-tax stock-based compensation cost?
Henry Schein (HSIC) reported pre-tax stock-based compensation cost of $3M in Q1 2026.
How has Henry Schein's pre-tax stock-based compensation cost changed year-over-year?
Henry Schein's pre-tax stock-based compensation cost decreased by 40.0% year-over-year, from $5M to $3M.
What is the long-term trend for Henry Schein's pre-tax stock-based compensation cost?
Over 4 years (2021 to 2025), Henry Schein's pre-tax stock-based compensation cost has grown at a -13.4% compound annual growth rate (CAGR), from $69.2M to $39M.